Valneva SE (INRLF)
OTCMKTS
· Delayed Price · Currency is USD
2.100
+0.220 (11.70%)
Dec 24, 2024, 4:00 PM EST
Valneva SE Employees
Valneva SE had 676 employees as of December 31, 2023. The number of employees decreased by 43 or -5.98% compared to the previous year.
Employees
676
Change (1Y)
-43
Growth (1Y)
-5.98%
Revenue / Employee
$261,565
Profits / Employee
-$12,239
Market Cap
335.03M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Sandoz Group AG | 22,633 |
Telix Pharmaceuticals Limited | 234 |
Elekta AB (publ) | 4,718 |
Ryman Healthcare Limited | 7,700 |
Verano Holdings Corp. | 3,900 |
Vireo Growth Inc. | 490 |
Medexus Pharmaceuticals Inc. | 82 |
Valneva SE News
- 7 days ago - Valneva Successfully Expands Access to Asia for its Chikungunya Vaccine with Serum Institute of India - GlobeNewsWire
- 22 days ago - Valneva Announces Peer-Reviewed Publication on the Global Health and Economic Burden of Chikungunya in The British Medical Journal - GlobeNewsWire
- 22 days ago - Valneva's Chikungunya Shot Shows Strong, Long-Lasting Antibody Persistence At Three Years, Comparable In Older And Younger Adults - Benzinga
- 23 days ago - Valneva Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ® - GlobeNewsWire
- 4 weeks ago - Valneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to the U.S. FDA - GlobeNewsWire
- 5 weeks ago - European And US Vaccine Stocks Are Under Pressure - Here's WHy - Benzinga
- 6 weeks ago - Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2 - GlobeNewsWire
- 6 weeks ago - Valneva SE (VALN) Q3 2024 Earnings Call Transcript - Seeking Alpha